122111-07-3

Upstream product

• 143234-90-6 Benzoic acid (R)-1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-ethoxycarbonyl-2,2-difluoro-ethyl ester 
• 95058-92-7 (erytro) ethyl-3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxy propionate 
• 98-88-4 benzoyl chloride 
• 1010839-84-5 ethyl (3RS)-3-(benzoyloxy)-2,2-difluoro-3-(2,2-dimethyldioxolan-4-yl)propionate 
• 143234-91-7 Benzoic acid (1R,2R)-1-(ethoxycarbonyl-difluoro-methyl)-2,3-dihydroxy-propyl ester 
• 928797-50-6 ethyl (3R,S)-2,2-difluoro-3-hydroxy-(2,2-dimethyldioxolpent-4-yl)propionate 

Downstream Products

• 1010839-85-6 C₂₀H₁₇F₂NO₇ 
• 1217526-42-5 (D-erythro,D-threo)-2-deoxy-2,2-difluoropentofuranos-1-ulose-3,5-dibenzoate 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATES OF 2,2' DIFLUORONUCLEOSIDES

The present invention provides novel 1-trihaloacetimido-2-deoxy-2,2'-difluoro-3,5-di-O-protected ribose intermediates. The compounds are useful in the preparation of 2'-deoxy-2,2'-difluoro-beta nucleosides and more particularly 2'-deoxy-2,2'-difluoro-beta cytidine and other beta anomer nucleosides and its salts having antiviral and anticancer activity

Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its use in the preparation of 2'-deoxy-2',2'-difluoro-β-D-ribofuranosyl pyrimidine nucleosides: The key role of selective crystallization

A stereospecific synthesis of 2'-deoxy-2',2'-difluorocytidine (gemcitabine), a potential anticancer agent, is described. The stereoselectivity was accomplished via two diastereoselective crystallizations, i.e. the crystallization of the key intermediate, difluororibonolactone 2a, and the crystallization of the hydrochloride salt of gemcitabine 16b from the anomeric mixture. Because of the availability of 2a in large quantities, other 2'-deoxy-2',2'-difluoropyrimidine nucleosides such as 2'-deoxy-2',2'-difluorouridine (19) were synthesized for structure-activity relationship studies.